I think I did a bad job highlighting the recent successes in my attempt to be comprehensive. And I probably shouldn’t have listed the iBCIs first, b/c readers will think that’s the state-of-the-art.
Definitely agree that non-medical BCI will have a slow adoption curve. As I discuss, though, they don’t need a fast adoption curve to be relevant to AI safety.
Seems like minimally invasive ultrasound, endovascular BCI, and optogenetic cell therapy all get around the “core barriers” you cite to CNS BCI.
None were around 15 years ago.
https://pubmed.ncbi.nlm.nih.gov/33756104/
https://clinicaltrials.gov/ct2/show/NCT03834857?term=synchron&draw=2 (endovascular BCI in humans)
https://www.biorxiv.org/content/10.1101/333526v1.full
I think I did a bad job highlighting the recent successes in my attempt to be comprehensive. And I probably shouldn’t have listed the iBCIs first, b/c readers will think that’s the state-of-the-art.
Definitely agree that non-medical BCI will have a slow adoption curve. As I discuss, though, they don’t need a fast adoption curve to be relevant to AI safety.